Pharmacogenomics for neurohormonal intervention in heart failure

Heart Fail Clin. 2005 Apr;1(1):141-50. doi: 10.1016/j.hfc.2004.10.001. Epub 2005 Jan 8.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Drug Evaluation
  • Heart Failure / drug therapy*
  • Heart Failure / genetics*
  • Humans
  • Mineralocorticoid Receptor Antagonists
  • Neurotransmitter Agents / genetics*
  • Nitric Oxide Synthase Type III / drug effects
  • Nitric Oxide Synthase Type III / genetics
  • Peptidyl-Dipeptidase A / genetics
  • Pharmacogenetics
  • Polymorphism, Genetic
  • Receptors, Adrenergic, beta / classification
  • Receptors, Adrenergic, beta / drug effects
  • Receptors, Adrenergic, beta / genetics
  • Risk Assessment / methods

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Mineralocorticoid Receptor Antagonists
  • Neurotransmitter Agents
  • Receptors, Adrenergic, beta
  • Nitric Oxide Synthase Type III
  • Peptidyl-Dipeptidase A